Why Athersys (ATHX) Stock Plummeted to a One-Year Low Today

NEW YORK (TheStreet) -- Athersys  (ATHX) plummeted more than 55% to a one-year low of $1.09 on Monday after the biotechnology company announced that its experimental stem-cell therapy to treat the inflammatory bowel disease ulcerative colitis did not show any benefits in patients in a mid-stage trial.

Athersys' partner Pfizer  (PFE) conducted the trial, in which the therapy did not show a statistically significant decrease in the severity of ulcerative colitis in patients with moderate to severe cases of the disease when compared to a placebo. The therapy also did not significantly reduce rectal bleeding when compared to a placebo.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ATHX Chart

ATHX data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers